ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the topline results of their Lupuzor Phase III trial. For full transcript click here
Tim McCarthy, Chairman of Immupharma discusses the topline results of the Lupuzor Pivotal Phase III Trial.
A great start to 2018 with pivotal Phase III data for Lupuzor™ only weeks away.
Tim McCarthy, Chairman of Immupharma discusses the completion of Lupuzor™ pivotal phase III study and initiation of follow up study.
ImmuPharma PLC (LON:IMM) is the topic of conversation when Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview.
Tim McCarthy talks to DirectorsTalk about its Lupuzor market update. Tim explains the main points to the update, the importance of reaching a milestone where all patients have been dosed for over three months, the importance of announcements to shareholders and confidence of providing top line results in Q1 2018.
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) tells Proactive they’re on schedule to publish first results from their phase III trial of lupus drug Lupuzor early next year with all 200 patients now having had at least three months worth of treatment.
Tim McCarthy, Chairman of ImmuPharma gives an update, on its lead compound, Lupuzor™ in its pivotal Phase III study on this audio podcast
Tim McCarthy, Chairman of ImmuPharma PLC , presents at the Biotech Capital Conference: 2017
Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) spoke to Proactive Investors to give an update on the company’s progress with its phase-III clinical trial of Lupuzor™, a treatment for Lupus – a life threatening auto-immune disease.
Tim McCarthy, Chairman of ImmuPharma talks to Vox Markets and gives update on their, Phase III Clinical Trials for its lead drug Lupuzor™.
Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about its phase 3 trial of Lupuzor. Tim explains the importance of completing the recruitment of the 200 patients and stay on track, the significance of the 70 patients that are being dosed in the US, detail on the Lupuzor safety profile and its importance, the market potential of Lupuzor if approved and key milestones for ImmuPharma in 2017/2018.
Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the keys points to take away from this update.
Tim McCarthy, Chairman of ImmuPharma talks to Proactive Investor, Vox Markets and Directors Talk on ImmuPharma being invited to open a new site in Mauritius, to enrol up to 30 Lupus patients. Click on the links below to see the interviews.